SAT1 siRNA Lipid Nanoparticles for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glioblastoma, a highly invasive and aggressive brain tumor, are limited by the inability of drugs to cross the blood-brain barrier and cause minimal adverse effects on non-tumor brain cells, leading to poor prognosis despite advances in cancer medicine.
Innovation Solution
Biocompatible lipid nanoparticles (LNPs) encapsulating siRNA to inhibit Spermidine/spermine N1-acetyltransferase 1 (SAT1) expression, combined with cadherin binding peptides to enhance delivery across the blood-brain barrier, are used to target and inhibit glioblastoma cell growth.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are used to treat glioblastoma, then tumor growth inhibition is achieved, but the drugs cannot cross the blood-brain barrier to reach the tumor
Solution Approach 1:
The patent uses lipid nanoparticles as intermediary carriers to transport siRNA across the blood-brain barrier. The LNPs are designed with specific lipid components that facilitate penetration through the barrier while delivering the therapeutic payload to tumor cells, thus resolving the barrier penetration issue without compromising tumor inhibition effectiveness.
Solution Approach 2:
The patent replaces conventional small molecule drug delivery with a nanoparticle-based delivery system that utilizes cellular uptake mechanisms. By substituting the delivery mechanism from passive diffusion to active cellular internalization via lipid nanoparticles, the system achieves effective brain tumor targeting while maintaining blood-brain barrier integrity.
2Reliability
If conventional chemotherapy and radiation are applied to glioblastoma, then tumor cells are killed, but non-GBM brain cells are damaged and the brain has limited repair capacity
Solution Approach 1:
The patent achieves local quality by delivering siRNA specifically to glioblastoma cells through blood-brain barrier penetration, rather than applying systemic chemotherapy that affects all brain cells. The lipid nanoparticle delivery system ensures that the therapeutic effect is localized to tumor cells expressing SAT1, spares non-tumor brain cells from cytotoxic damage, and leverages the limited brain repair capacity by avoiding widespread cellular injury.
3Productivity
If SAT1 expression is inhibited in glioblastoma cells, then tumor proliferation is reduced, but the delivery system must cross the blood-brain barrier which limits drug access
Solution Approach 1:
The patent employs lipid nanoparticles as intermediary carriers that facilitate SAT1-targeted siRNA delivery across the blood-brain barrier. The LNPs are engineered with specific lipid compositions that enable efficient barrier penetration while maintaining siRNA stability and cellular uptake, thus achieving tumor proliferation reduction without compromising delivery accessibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNP-siRNA compositions effectively reduce glioblastoma cell proliferation with minimal toxicity to non-tumor cells, potentially reducing chemotherapy and radiation requirements and improving patient survival.
Implementation Method 1
an ionizable cationic lipid (e.g., ionizable cationic unsaturated lipid) having a polar head group with a pKa of below 7
Implementation Method 2
cadherin binding peptides to enhance LNP delivery across the blood-brain barrier
Data Source
AI summary
Described herein is a biocompatible lipid nanoparticle (LNP) composition suitable for delivering RNA payloads into cells and tissues of a subject. The biocompatible LNPs comprise an ionizable cationic lipid as a core component and have a net neutral surface charge at physiological pH. Delivery of LNP-encapsulated siRNA inhibiting the expression Spermidine/spermine N1-acetyltransferase 1 (SAT1) is shown to inhibit proliferation of a glioblastoma cell line, but not in other cells pertinent to brain tissue such as microvascular endothelial cells, primary human astrocytes, and macrophage cells. Use of a cadherin-binding peptide to increase delivery of LNP-encapsulated siRNA across a blood-brain barrier monolayer model is also described.